Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.

Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, recently shared a post by The Lancet Oncology on X/Twitter, adding:

“Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed. FOLFOX plus regorafenib and nivolumab for advanced EG cancer. ORR 76% and 6-month PFS 71%. Nice work, Sam Cytryn and team!”

Quoting The Lancet Oncology’s post:

“NOW OF: A US single-arm, single-center, phase 2 trial assesses the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma.”

For the article click here.
Source: Ryan Moy/Twitter and The Lancet Oncology/Twitter